comparemela.com

Latest Breaking News On - Director simon - Page 17 : comparemela.com

Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Misses Expectations By $0 01 EPS

Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01), Briefing.com reports. Xenon Pharmaceuticals had a negative net margin of 862.06% and a negative return on equity of 17.90%. During the same […]

Xenon Pharmaceuticals (NASDAQ:XENE) Announces Earnings Results, Misses Estimates By $0 01 EPS

Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01), Briefing.com reports. Xenon Pharmaceuticals had a negative net margin of 862.06% and a negative return on equity of 17.90%. During the same quarter […]

Xenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Misses Expectations By $0 01 EPS

Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01), Briefing.com reports. Xenon Pharmaceuticals had a negative net margin of 862.06% and a negative return on equity of 17.90%. During the same […]

Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year High at $41 60

Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Rating) hit a new 52-week high during trading on Thursday . The stock traded as high as $41.60 and last traded at $41.36, with a volume of 443718 shares changing hands. The stock had previously closed at $40.78. Wall Street Analyst Weigh In Several equities analysts have […]

Xenon Pharmaceuticals (NASDAQ:XENE) Earns Overweight Rating from Analysts at Cantor Fitzgerald

Cantor Fitzgerald began coverage on shares of Xenon Pharmaceuticals (NASDAQ:XENE – Get Rating) in a report released on Tuesday, The Fly reports. The brokerage issued an overweight rating and a $58.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Xenon Pharmaceuticals’ FY2023 earnings at ($2.71) EPS. XENE has been the […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.